In breast cancer, lag3, pdcd1, and klrk1 are positively correlated with the abundance of CD8+T and CD4+T cells (Figure 3E), suggesting that LAG3 may be a potential immunotherapeutic target in breast cancer, especially for TNBC and TP53 mutant breast cancer. This evidence concerns the gene CD4 and breast cancer.